Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment

Detalles Bibliográficos
Autores principales: Robinson, Philip C, Richards, Duncan, Tanner, Helen L, Feldmann, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832144/
https://www.ncbi.nlm.nih.gov/pubmed/33521660
http://dx.doi.org/10.1016/S2665-9913(20)30309-X
_version_ 1783641770481942528
author Robinson, Philip C
Richards, Duncan
Tanner, Helen L
Feldmann, Marc
author_facet Robinson, Philip C
Richards, Duncan
Tanner, Helen L
Feldmann, Marc
author_sort Robinson, Philip C
collection PubMed
description
format Online
Article
Text
id pubmed-7832144
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-78321442021-01-26 Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment Robinson, Philip C Richards, Duncan Tanner, Helen L Feldmann, Marc Lancet Rheumatol Comment Elsevier Ltd. 2020-11 2020-09-05 /pmc/articles/PMC7832144/ /pubmed/33521660 http://dx.doi.org/10.1016/S2665-9913(20)30309-X Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Comment
Robinson, Philip C
Richards, Duncan
Tanner, Helen L
Feldmann, Marc
Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment
title Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment
title_full Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment
title_fullStr Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment
title_full_unstemmed Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment
title_short Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment
title_sort accumulating evidence suggests anti-tnf therapy needs to be given trial priority in covid-19 treatment
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832144/
https://www.ncbi.nlm.nih.gov/pubmed/33521660
http://dx.doi.org/10.1016/S2665-9913(20)30309-X
work_keys_str_mv AT robinsonphilipc accumulatingevidencesuggestsantitnftherapyneedstobegiventrialpriorityincovid19treatment
AT richardsduncan accumulatingevidencesuggestsantitnftherapyneedstobegiventrialpriorityincovid19treatment
AT tannerhelenl accumulatingevidencesuggestsantitnftherapyneedstobegiventrialpriorityincovid19treatment
AT feldmannmarc accumulatingevidencesuggestsantitnftherapyneedstobegiventrialpriorityincovid19treatment

Ejemplares similares